Molecular and imaging biomarkers of primary and metastatic liver tumors

Sunday, March 5, 2023

8:30 AM – 10:00 AM

Location:Phoenix Convention Center, 222AB

CE: 1.5 Credits

Coordinator(s)

Nadine Abi-Jaoudeh, MD, FSIR

Professor of Radiology
University of California

Disclosure(s): Angiodynamics Inc: Contracted Research (Ongoing); AstraZeneca: Consultant (Ongoing); BlackSwan Vascular Inc: Contracted Research (Terminated, November 7, 2022); Bruin Biosciences Inc.: Ownership Interest (Ongoing); Eisai Co., Ltd: Advisory Committee or Review Panel Member (Terminated, April 15, 2021); Genentech F. Hoffmann-La Roche Ltd: Consultant (Ongoing); Guerbet SA: Research Grant Recipient (Ongoing); Histosonics Inc.: Data safety Monitoring Board (Ongoing); Innova Vascular Inc: Advisory Committee or Review Panel Member (Ongoing); Instylla HES Inc: Contracted Research (Ongoing); Johnson and Johnson: Consultant (Ongoing); Lynx Group LLC: Advisory Committee or Review Panel Member (Terminated, January 27, 2022); Medtronic Inc: Advisory Committee or Review Panel Member (Terminated, April 30, 2021); Pfizer Inc: Advisory Committee or Review Panel Member (Terminated, October 15, 2021); Philips Medical Systems Inc Koninklijke NV: Research Grant Recipient (Ongoing); QED Therapeutics Inc: Advisory Committee or Review Panel Member (Terminated, February 1, 2021); Sirtex Medical Ltd: Contracted Research (Ongoing); Teclison Limited (PI): Research Grant Recipient (Ongoing)

Disclosure(s):

Nadine Abi-Jaoudeh, MD, FSIR: Angiodynamics Inc: Contracted Research (Ongoing); AstraZeneca: Consultant (Ongoing); BlackSwan Vascular Inc: Contracted Research (Terminated, November 7, 2022); Bruin Biosciences Inc.: Ownership Interest (Ongoing); Eisai Co., Ltd: Advisory Committee or Review Panel Member (Terminated, April 15, 2021); Genentech F. Hoffmann-La Roche Ltd: Consultant (Ongoing); Guerbet SA: Research Grant Recipient (Ongoing); Histosonics Inc.: Data safety Monitoring Board (Ongoing); Innova Vascular Inc: Advisory Committee or Review Panel Member (Ongoing); Instylla HES Inc: Contracted Research (Ongoing); Johnson and Johnson: Consultant (Ongoing); Lynx Group LLC: Advisory Committee or Review Panel Member (Terminated, January 27, 2022); Medtronic Inc: Advisory Committee or Review Panel Member (Terminated, April 30, 2021); Pfizer Inc: Advisory Committee or Review Panel Member (Terminated, October 15, 2021); Philips Medical Systems Inc Koninklijke NV: Research Grant Recipient (Ongoing); QED Therapeutics Inc: Advisory Committee or Review Panel Member (Terminated, February 1, 2021); Sirtex Medical Ltd: Contracted Research (Ongoing); Teclison Limited (PI): Research Grant Recipient (Ongoing)

To review molecular and imaging biomarkers of primary and metastatic liver cancers and their implications on IO therapy treatment response

Learning Objectives:

Upon completion, participants will be able to define the role of hypoxia as a factor in tumor resistance to radiation-based therapies and strategies to make tumors radio-sensitive
Upon completion, participants will be able to describe imaging and molecular biomarkers that predict favorable tumor response pre-therapy
Upon completion, participants will be able to describe imaging and molecular biomarkers of early treatment response post liver-directed IO therapies

Presentations:

8:30 AM – 8:40 AM

Hypoxia activated agents and radiosensitizers
Speaker: Nadine Abi-Jaoudeh, MD, FSIR – University of California
8:40 AM – 8:50 AM

Hypoxia and radio-resistance
Speaker: Nima Kokabi, MD – Emory School of Medicine
8:50 AM – 9:00 AM

Anatomical Imaging Biomarkers: Diffusion and perfusion imaging
Speaker: Mishal Mendiratta-Lala, MD – University of Michigan
9:00 AM – 9:10 AM

Functional Imaging Biomarkers: PET
Speaker: Juan C. Camacho, MD (he/him/his) – Radiology Associates of Florida, Florida State University
9:10 AM – 9:20 AM

Primary Liver Tumors: Genomic and molecular biomarkers for HCC and Cholangiocarcinoma
Speaker: Terence P. Gade, MD PhD – Penn Image-Guided Interventions (PIGI) Lab, Hospital of the University of Pennsylvania
9:20 AM – 9:30 AM

Metastatic Liver Tumors: Genomic and molecular biomarkers for CRC, neuroendocrine
Speaker: Daniel B. Brown, M.D. – Vanderbilt University Medical Center
9:30 AM – 9:40 AM

Breast Cancer: Genomic and molecular biomarkers
Speaker: Dania Daye, MD, PhD – Massachusetts General Hospital/ Harvard Medical School
9:40 AM – 9:50 AM

Pressure-Enabled Tumor Drug Delivery
Speaker: Alexander Y. Kim, MD FSIR – National Vascular Physicians
9:50 AM – 10:00 AM

Q & A